Icodextrin solution - Innovata

Drug Profile

Icodextrin solution - Innovata

Alternative Names: Adept®; Extraneal; Icodextrin solution; Icodial®

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innovata
  • Developer Baxter Healthcare Corporation; Shire
  • Class Glucans; Hexoses
  • Mechanism of Action Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Kidney disorders
  • New Molecular Entity No

Highest Development Phases

  • Marketed Kidney disorders
  • Phase II Hypertriglyceridaemia
  • No development reported Heart failure

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 09 Mar 2007 Phase-II clinical trials in Congestive heart failure in Australia (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top